-Genosaber

Background

Founded in 2011, Genosaber Biotech is the world's first developer of liquid biopsy kits for lung cancer circulating tumor cells (CTCs) and circulating tumor DNA   (ctDNA) quantification. The company is dedicated to creating products that enable real-time tracking of tumor dynamics and provide timely pathological evidence for patients.

Its "liquid biopsy" technologies have received numerous international and domestic awards for technical innovation and academic contributions.

Genosaber collaborates globally with top-tier research and clinical institutions (e.g., Mayo Clinic, UCLA Medical Center, Chinese Academy of Medical Sciences Cancer Hospital) to advance clinical applications.

The company’s R&D achievements were honored with the Second Prize of National Science and Technology Progress Award (2019). By 2025, Genosaber holds 76 trademarks and 48 patents.